IFB02

IFB02 is a sactipeptide therapeutic candidate being developed by Interface Biosciences, currently in the optimization phase of preclinical development. It is designed to modulate the activity of the chemokines C-C motif chemokine ligand 20 (CCL20) and C-X-C motif chemokine ligand 10 (CXCL10). These chemokines are key mediators in the recruitment of inflammatory cells, such as Th17 and Th1 cells, to diseased tissues. By targeting these pathways, IFB02 is intended for the treatment of chronic inflammatory conditions, including Rheumatoid Arthritis and Inflammatory Bowel Disease, as well as potential applications in Oncology to alter the immune landscape of the tumor microenvironment. As a sactipeptide, IFB02 belongs to a class of ribosomally synthesized and post-translationally modified peptides (RiPPs) characterized by sulfur-to-alpha-carbon thioether cross-links, which can provide enhanced stability and specificity.